Lung cancer, a leading cause of cancer-related deaths globally, is characterized by significant genomic instability, which is a hallmark of various cancers.

A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored.

T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...

Oncology nurses play essential roles in the emerging field of cardio-oncology, which aims to protect patients’ heart function ...

Thoracic medical oncologist at Yale Medicine, Dr Anne Chiang asserted: "We used to think all lung cancers were the same, but now we understand that there are different kinds." It is common for non ...

The Birmingham VA Health Care System showed off its robotic-assisted tools available to veterans for early lung cancer ...

which investigate mechanisms of carcinogenesis of thoracic cancers, explore cancer-immune system microenvironments, and examine ischemia-reperfusion injury in lung transplantation. We treat all ...

Investigators are developing this BH3 profiling technique for use in solid thoracic cancers with the goal of providing patient-specific, precision treatments by specific targeting of anti-apoptotic ...

Clinical trials to develop a lung cancer vaccine to treat or prevent the most deadly form of cancer in the U.S. could be ...

The 2017 Multidisciplinary Thoracic Cancers Symposium, co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and The Society of Thoracic ...

Professor Jae-Ho Chung said, "Thoracic surgery departments in three ... and Propensity Score-Matched Study, Cancers (2024).